The GLS1 selective inhibitor, CB-839, is currently under evaluation for treatment of hematological malignancies and solid tumors, and early indications from a phase 1 study in MM suggests that CB-839 is well tolerated as a monotherapy [21–23]. This evidence concerns the gene GLS and Miyoshi myopathy.